JDD Highlights
The October issue of the Journal of Drugs in Dermatology is available now. This month, we focus on atopic dermatitis with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.
Read the October JDD Now
Atopic Dermatitis, Public Health, Anti-Aging, and Medical Dermatology
The October issue of the Journal of Drugs in Dermatology is available now. This month, we focus on atopic dermatitis, with special features on Public Health, Anti-aging, Aesthetic, and Medical Dermatology.
Article Highlights
- Clinical Relevance of Skin Pain in Atopic Dermatitis discusses the clinical relevance of skin pain with respect to its experience, pathophysiology, relationship with itch, and treatment implications.
- A roundtable discussion was held to discuss overall and specific strategies for treating rosacea in Rationale for Use of Combination Therapy in Rosacea
- Results from an expert panel were summarized and discussed to provide updated recommendations for the treatment and maintenance of AD in Atopic Dermatitis and the Role of the Skin Microbiome in Choosing Prevention, Treatment, and Maintenance Options
- Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study reports the impact of specific AD lesion locations on QoL in adult patients with AD using real-world data
Editor's Picks
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines
- Hyaluronidase in Dermatology: Uses Beyond Hyaluronic Acid Fillers
You May Also Like
Physician’s Weekly interviewed dermatologist Geeta Yadav, MD, for her perspective on the March Journal of Drugs in Dermatology study, “Expert Consensus on Advanced Topical Nonsteroidal Therapies for Chronic Hand Eczema.”…
Topical Metformin versus Kligman’s Formula for Melasma, a Split-Face JDD Study This is a must-read article from JDD a head-to-head split-face study asks whether topical metformin can be an effective,…
Extended Pembrolizumab Duration Tied to Lower Mortality in Stage III and IV Melanoma: JDD Report Could extending pembrolizumab improve survival? This JDD is a must read. A new retrospective analysis…
